2023 Full-Year Financial Guidance1
The Company's full-year guidance for 2023 can be found in the table below. No updates were made to the previous guidance that was issued on February 23,
The FDA approved a supplemental marketing application for Biogen Inc (NASDAQ: BIIB)-Eisai Co Ltd (OTC: ESALY) supporting the traditional approval of Leqembi (lecanemab-irmb), making it the first and only ap